| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| ln Vitro |
4'-Demethylepipodophyllotoxin has antibacterial actions on Xanthomonas oryzae pv (EC50 = 38.7 μg/mL) and decreases XooFtsZ'GTPase activity [3]. The cytotoxic effect of 4'-Demethylepipodophyllotoxin (Xoo) against tumor cells is demonstrated by its EC50 values of 0.31, 0.32, 0.37, and 0.43 μM for HepG2, KB, HL-60, and K-562 cells [1].
The compound showed cytotoxicity against a panel of human tumor cell lines: HL-60 (EC50 = 0.31 μM), K-562 (EC50 = 0.32 μM), HepG2 (EC50 = 0.37 μM), KB (EC50 = 0.43 μM), and BGC-823 (EC50 = 398.05 μM). Against the normal human proximal tubular epithelial cell line HK-2, the EC50 was 38.73 μM [1]. |
|---|---|
| ln Vivo |
In a DMBA/TPA-induced skin carcinogenesis model, 4'-Demethylepipodophyllotoxin (1 µg/mL, 200 µL, topical, 24 weeks) decreases tumor incidence, tumor volume, and papilloma-to-squamous cell carcinoma transformation efficiency [1].
|
| Cell Assay |
Cytotoxicity was evaluated using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cells (3,500 to 13,000 per well) were seeded into 96-well microtest plates with 100 μL culture medium per well. Cells were treated in triplicate with gradient concentrations of the test compound and incubated at 37°C in RPMI 1640 medium supplemented with 100 mg/L mancyamin and 10% (v/v) fetal bovine serum in a humidified atmosphere containing 5% CO2 for 48 hours. Drug stock solutions were prepared in DMSO, and the final solvent concentration was ≤2% (v/v) DMSO. After 2 days of drug exposure, the MTT assay was performed to measure cytotoxic effects. The 50% effective concentration (EC50), defined as the drug concentration that reduced the absorbance by 50%, was interpolated from dose-response data. Each test was performed in triplicate, and absorbance readings varied no more than 5%. Initial seeding densities varied among cell lines to ensure a final absorbance reading in control (untreated) cultures in the range of 0.6 to 0.8 A402 units [1].
|
| Toxicity/Toxicokinetics |
Against the normal human proximal tubular epithelial cell line HK-2, the EC50 was 38.73 μM, indicating its cytotoxic effect on normal cells [1].
|
| References |
|
| Additional Infomation |
4'-Demethylepiotopotoxin is an organic heterotetracyclic compound, the 9-epidermose of 4'-demethylepiotopotoxin. It possesses antitumor activity. It is a furanonaphthalenedioxane heterocyclic compound, belonging to the organic heterotetracyclic class of compounds, and is also a member of the phenolic class.
4'-Demethylepipodophyllotoxin (product 1) is a biotransformation product of podophyllotoxin, obtained by demethylation of the methoxyl group at the 4' position of podophyllotoxin using Gibberella fujikuroi SH-f13. It was isolated as a white needle with purity >97% and identified by NMR and ESI-MS. The compound served as an intermediate for further biotransformation into 4'-demethylpodophyllotoxone and eventually into the novel compound 4-TMP-DMEP [1]. |
| Molecular Formula |
C21H20O8
|
|---|---|
| Molecular Weight |
400.3787
|
| Exact Mass |
400.115
|
| CAS # |
6559-91-7
|
| PubChem CID |
122797
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
626.5±55.0 °C at 760 mmHg
|
| Melting Point |
246-248ºC
|
| Flash Point |
224.4±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.638
|
| LogP |
0.71
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
29
|
| Complexity |
614
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1C([C@]2([H])[C@]([H])(C3C([H])=C(C(=C(C=3[H])OC([H])([H])[H])O[H])OC([H])([H])[H])C3=C([H])C4=C(C([H])=C3[C@]([H])([C@@]2([H])C1([H])[H])O[H])OC([H])([H])O4)=O
|
| InChi Key |
YVCVYCSAAZQOJI-JHQYFNNDSA-N
|
| InChi Code |
InChI=1S/C21H20O8/c1-25-15-3-9(4-16(26-2)20(15)23)17-10-5-13-14(29-8-28-13)6-11(10)19(22)12-7-27-21(24)18(12)17/h3-6,12,17-19,22-23H,7-8H2,1-2H3/t12-,17+,18-,19+/m0/s1
|
| Chemical Name |
(5S,5aR,8aR,9R)-5-hydroxy-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~3.33 mg/mL (~8.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4976 mL | 12.4881 mL | 24.9763 mL | |
| 5 mM | 0.4995 mL | 2.4976 mL | 4.9953 mL | |
| 10 mM | 0.2498 mL | 1.2488 mL | 2.4976 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00026208 | COMPLETEDWITH RESULTS | Drug: Vincristine Drug: Cyclophosphamide Drug: Doxorubicin |
Hodgkin Disease Lymphoma Lymphoma, Hodgkin Disease Lymphoma: Hodgkin |
Stanford University | 2001-06 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
